Soclenicant

Last updated
Soclenicant
IW-2143 molecular structure.png
Clinical data
Other namesBNC210; BNC-210; IW2143; IW-2143; L-Isoleucyl-L-tryptophan
Routes of
administration 		Oral
Drug class α7-Nicotinic acetylcholine receptor negative allosteric modulator
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Bioavailability 69.4% (rat) [1] [2]
Protein binding 70–88% [1] [2]
Elimination half-life 6.2 hours (rat) [1] [2]
Identifiers
  • L-isoleucyl-L-tryptophan
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C17H23N3O3
Molar mass 317.389 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N
  • InChI=1S/C17H23N3O3/c1-3-10(2)15(18)16(21)20-14(17(22)23)8-11-9-19-13-7-5-4-6-12(11)13/h4-7,9-10,14-15,19H,3,8,18H2,1-2H3,(H,20,21)(H,22,23)/t10-,14-,15-/m0/s1
  • Key:BVRPESWOSNFUCJ-LKTVYLICSA-N

Soclenicant (INN Tooltip International Nonproprietary Name), [3] also known by its developmental code names BNC210 and IW-2143 and as L-isoleucyl-L-tryptophan, is an antinicotinic agent which is under development for the treatment of anxiety disorders such as social phobia and generalized anxiety disorder, as well as for treatment of agitation, post-traumatic stress disorder (PTSD), and depressive disorders. [1] [4] [5] It is taken by mouth. [4]

The drug acts as a highly selective negative allosteric modulator (NAM) of the α7-nicotinic acetylcholine receptor (α7-nAChR). [1] [6] [4] [5] It produces anxiolytic-, anti-stress-, and antidepressant-like effects without causing sedation, memory or motor impairment, or physical dependence in rodents. [6] Chemically, soclenicant is a dipeptide of the amino acids L-tryptophan and L-isoleucine and can be considered a tryptamine derivative. [7]

Soclenicant is being developed by Bionomics. [4] It has also been developed by Ironwood Pharmaceuticals and EmpathBio. [4] [5] Bionomics was acquired by Neuphoria Therapeutics in December 2024. [4] As of December 2024, soclenicant is in phase 3 clinical trials for anxiety disorders, phase 2 trials for agitation and PTSD, and no recent development has been reported for depressive disorders. [4] [5] The drug received Fast Track designation from the United States Food and Drug Administration (FDA) in 2019. [8] It was first described in the literature, in a conference abstract, by 2007. [2]

See also

References

  1. 1 2 3 4 5 Hampsey E, Perkins A, Young AH (April 2023). "BNC210: an investigational α7-nicotinic acetylcholine receptor modulator for the treatment of anxiety disorders". Expert Opin Investig Drugs. 32 (4): 277–282. doi:10.1080/13543784.2023.2192922. PMID   36927202.
  2. 1 2 3 4 Andriambeloson, E., Wagner, S., Huyard, B., Sleebs, B., Quasi, N., Bui, C., ... & Street, I. (2007, September). BNC210: A Novel Compound with Potent Anxiolytic Activity. In Behavioral Pharmacology (Vol. 18, pp. S16–S16). https://neurofit.com/im-posters/2008-ebps-bnc210.pdf
  3. ↑ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf#page=198 soclenicantum soclenicant 6-[(2,3-dihydro-1H-inden-2-yl)amino]-1-ethyl-3-(morpholine4-carbonyl)-1,8-naphthyridin-4(1H)-one nicotinic acetylcholine receptor negative allosteric modulator, anxiolytic
  4. 1 2 3 4 5 6 7 "BNC 210". AdisInsight. 30 December 2024. Retrieved 22 February 2025.
  5. 1 2 3 4 "Delving into the Latest Updates on BNC-210 with Synapse". Synapse. 23 January 2025. Retrieved 22 February 2025.
  6. 1 2 O'Connor SM, Sleebs BE, Street IP, Flynn BL, Baell JB, Coles C, Quazi N, Paul D, Poiraud E, Huyard B, Wagner S, Andriambeloson E, de Souza EB (March 2024). "BNC210, a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor, demonstrates anxiolytic- and antidepressant-like effects in rodents". Neuropharmacology. 246: 109836. doi: 10.1016/j.neuropharm.2024.109836 . PMID   38185416.
  7. ↑ "CID 7019084". PubChem. Retrieved 22 February 2025.
  8. ↑ Bionomics Limited Press Release (2019-11-04). "Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD". BusinessWire. Retrieved 2020-09-09.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.